Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program

BACKGROUND: Lenalidomide, a novel immunomodulatory agent, is reported to modulate stem cell differentiation, and have direct antiproliferative activity as well as inhibit inflammation and hyperalgesia. On the basis of this varied pharmacological profile, lenalidomide is under investigation as a trea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Maris, John M., Carol, Hernan, Morton, Christopher L., Billups, Catherine A., Smith, Malcolm A., Houghton, Peter J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505747/
https://ncbi.nlm.nih.gov/pubmed/21360651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22877
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky